Related references
Note: Only part of the references are listed.Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer
Mercedes Marin-Aguilera et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Characterisation and manipulation of docetaxel resistant prostate cancer cell lines
Amanda J. O'Neill et al.
MOLECULAR CANCER (2011)
Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer
Tanya B. Dorff et al.
CLINICAL CANCER RESEARCH (2010)
Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells
Frederic R. Santer et al.
ENDOCRINE-RELATED CANCER (2010)
Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer
B. Mellado et al.
BRITISH JOURNAL OF CANCER (2009)
Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling
Liangli Zhao et al.
CANCER RESEARCH (2009)
Tumor Self-Seeding by Circulating Cancer Cells
Mi-Young Kim et al.
CELL (2009)
Interleukin-6 Regulates Androgen Synthesis in Prostate Cancer Cells
Jae Yeon Chun et al.
CLINICAL CANCER RESEARCH (2009)
Inflammation and cancer: how friendly is the relationship for cancer patients?
Bharat B. Aggarwal et al.
CURRENT OPINION IN PHARMACOLOGY (2009)
IKK/NF-κB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis
Julia Bollrath et al.
EMBO REPORTS (2009)
Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor
Kamilla Malinowska et al.
ENDOCRINE-RELATED CANCER (2009)
New Insights Into the Role of Interleukin-6 in Human Prostate Cancer
Zoran Culig
JOURNAL OF UROLOGY (2009)
Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2
Siting Feng et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel
J. Domingo-Domenech et al.
ANNALS OF ONCOLOGY (2008)
The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells
Marina Zemskova et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer
Michael J. Morris et al.
JOURNAL OF UROLOGY (2007)
The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1
I. T. Cavarretta et al.
ONCOGENE (2007)
Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328
Hannes Steiner et al.
PROSTATE (2006)
Interleukin 6, a nuclear factor-κB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-κB inhibition by PS-1145 enhances docetaxel antitumor activity
Josep Domingo-Domenech et al.
CLINICAL CANCER RESEARCH (2006)
Nuclear factor-κB in cancer development and progression
Michael Karin
NATURE (2006)
Activation of nuclear factor-κB in human prostate carcinogenesis and association to biochemical relapse
J Domingo-Domenech et al.
BRITISH JOURNAL OF CANCER (2005)
Blockage of NF-κB induces serine 15 phosphorylation of mutant p53 by JNK kinase in prostate cancer cells
LF Zerbini et al.
CELL CYCLE (2005)
Biological and chemical inhibitors of NF-κB sensitize SiHa cells to cisplatin-induced apoptosis
M Venkatraman et al.
MOLECULAR CARCINOGENESIS (2005)
Inactivation of nuclear factor κB by soy isoflavone genistein contributes to increased apoptosis mduced by chemotherapeutic agents in human cancer cells
YW Li et al.
CANCER RESEARCH (2005)
The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: Results from cancer and leukemia group B 9480
DJ George et al.
CLINICAL CANCER RESEARCH (2005)
Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells
YS Pu et al.
PROSTATE (2004)
NF-kappa B activation in human prostate cancer: Important mediator or epiphenomenon?
J Suh et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2004)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Multiple transcription factors regulating the IL-6 gene are activated by cAMP in cultured Caco-2 cells
DD Hershko et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2002)
Share Paper
